链球菌 722制剂是上海医药工业研究院经过多年研究而试制成功的一种新的具有非特异性免疫赋活作用的抗肿瘤药物,与国外称作Picibanil(OK-432)的抗肿瘤免疫药物相似。Picibani自1967年在日本问世以来,在各种癌症化疗领域里都取得良好的临床效果,并于1975年1月获得日本政府的正式批准生产。近二十年来,Picibanil(OK-423) Streptococcus 722 is a new anti-tumor drug with nonspecific immune activation trial successfully developed by Shanghai Institute of Pharmaceutical Industry for many years and resembles the anti-tumor immune drug called Picibanil (OK-432) abroad. Since Picibani was introduced in Japan in 1967, Picibani has achieved good clinical results in various cancer chemotherapies and was officially approved by the Japanese government in January 1975. For nearly two decades, Picibanil (OK-423)